NCT02135042 2026-03-18
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
NRG Oncology
National Cancer Centre, Singapore
Mateon Therapeutics
Bristol-Myers Squibb